A NOTE FROM THE ASSOCIATE VICE CHANCELLOR, PRESIDENT AND CEO
Welcome and introduction of the first edition of the UCLA Technology Development Group's Annual Newsletter

BOEHRINGER-INGELHEIM & UCLA COLLABORATE ON CANCER VACCINE PLATFORM FOR IMMUNOTHERAPY
Boehringer-Ingelheim & UCLA are collaborating on a several-year effort to develop a new cancer vaccine platform for immunotherapy
A NOTE FROM THE ASSOCIATE VICE CHANCELLOR, CEO & PRESIDENT

I would like to welcome you to the remodeled UCLA Technology Development Group (TDG) Annual Newsletter. We are excited to launch this resource and see its evolution as it continues.

It has been a little over a year since I assumed the Office of the Associate Vice Chancellor of the Technology Development Group at UCLA, and what an exciting time to be part of UCLA and TDG.

I’m pleased to share we’ve made quite a few positive and effective changes to the organization and structure of our division and team. With the assistance of business management consultants, Fuentek LLC, we evaluated our strengths and weaknesses of the organization and set forth to make improvements. With the results from Fuentek’s in-depth evaluation, and through attrition, we’ve had the opportunity to strengthen and reimage our team and brand with the hiring of 16 new team members and 3 new Board Members that have new perspectives and philosophies. We’ve also updated our name from, the Office of Intellectual Property and Industry Sponsored Research, to the Technology Development Group to reflect our refined image and focus.

The team has committed themselves to new policies, procedures and platforms. We’ve integrated Inteum, an industry leading technology transfer software solution, in our daily practice. Inteum has been a significant value-add to our division as it allows us to effectively manage intellectual property, licensing operations and marketing projects.

UCLA TDG aspires to serve as a campus-wide gateway to Innovation, Research and Entrepreneurship. I would like to encourage you to spend some time getting to know TDG and our new team members and I look forward to establishing strategic partnerships.

Amir Naiberg

STAFF ADDITIONS

UCLA TDG BOARD OF DIRECTORS

3 BOARD MEMBERS

MARKETING

2 MARKETING MANAGER & TECH TRANSFER ASSOCIATE

OPERATIONS

3 EXECUTIVE ASSISTANT HR & OPERATIONS MANAGER AND A RECEPTIONIST

LICENSING

8 DIRECTOR OF CONTRACTS, SR. DIRECTOR OF BIO PHARMACEUTICALS, TTO (DATABASE & COMP SCIENCE), THREE TECH TRANSFER OFFICERS, A PATENT PROSECUTION ANALYST AND A LICENSING SUPPORT ANALYST

NEW VENTURES

2 NEW VENTURES PRINCIPAL & NEW VENTURES SENIOR ASSOCIATE

INDUSTRY RESEARCH & MATERIAL TRANSFER

1 IR-MT ASSOCIATE
UCLA TECHNOLOGY DEVELOPMENT GROUP BOARD OF DIRECTORS

The TDG Board of Directors is comprised of distinguished UCLA faculty and executives from a range of industries, including biopharmaceuticals, engineering, finance, private equity, and venture capital. Board members provide guidance in making strategic investment decisions, oversight and direction to TDG’s activities.
FY2016 FACTS & FIGURES

138 CALIFORNIA COMPANIES COMMERCIALIZING UCLA DISCOVERIES

UCLA is among the nation’s leading universities supporting and creating startups.

Number of Companies
- 1
- 2 - 4
- 5 - 9

Maps courtesy of UCLA Government & Community Relations

FY2017 FACTS & FIGURES

152 CALIFORNIA COMPANIES COMMERCIALIZING UCLA DISCOVERIES

UCLA is among the nation’s leading universities supporting and creating startups.

Number of Companies
- 1
- 2 - 4
- 5 - 9

Maps courtesy of UCLA Government & Community Relations
LA BioMed has sold their royalty rights to Kybella®, the first and only FDA-approved injectable drug to treat submental fullness, that was originally developed by LA BioMed and UCLA researchers. Allergan, a global pharmaceutical company, is marketing Kybella® for the treatment of submental fullness.

“This agreement will greatly enhance LA BioMed’s research enterprise by providing us with substantial new revenues and greater certainty about the income stream from the development of this treatment for submental fullness,” said David I. Meyer, PhD, LA BioMed president, and CEO. “With this agreement, we are strategically supporting the funding of research that will benefit patients both here and around the globe.”

Keith B. Hoffman, PhD, LA BioMed vice president of business development and technology transfer, said the agreement required complex coordination from multiple parties. “I would like to personally commend our LA BioMed Monetization Committee, colleagues at UCLA, top-tier bankers at Morgan Stanley, and the excellent team of lawyers at Ropes & Gray and Pillsbury Winthrop Shaw Pittman LLP,” he said. “This transaction is further evidence that LA BioMed is committed to its entrepreneurial vision and increasing the range of its commercial activities. We are focused on commercializing our intellectual capital in order to foster further research.”

Morgan Stanley & Co. LLC acted as sole structuring agent for the transaction. Ropes & Gray and Pillsbury Winthrop Shaw Pittman LLP served as legal counsel for the transaction.


School: UCLA School of Medicine
UCLA INNOVATION FUND
2017 BIOMEDICAL COMPETITION

In order to advance therapeutics, medical devices/diagnostics, and digital health technologies across campus, the Technology Development Group (TDG), UCLA Health / David Geffen School of Medicine (DGSOM), UCLA School of Dentistry, UCLA Henry Samueli School of Engineering & Applied Science and the College’s Divisions of Life Sciences and Physical Sciences have collaborated to present the UCLA Innovation Fund. This opportunity is open to UCLA faculty from all Schools who have signed the UCLA Patent Policy.

The fund has a singular mission: To enable technologies to move quickly from the lab to the market, and bridge the gap between academic research and industry/venture capital interest.

Funding will be used to advance a project along to reach a key project-specific milestone, further enabling these technologies to be licensed to an existing company or a startup. These funds are to support commercialization activities that would not be supported by basic research grants.

There is a three-step application process, which requires a Letter of Intent, Full Application (by invitation only), and a Pitch Presentation.

2017 Process and Timeline:
- Letters of Intent (LOI) due (all tracks), May 30
- LOI decisions announced (all tracks), June 19
- Therapeutic track applications due, July 17
- Medical devices/diagnostics, August 31
- Digital health technologies, October 23
- Therapeutics Pitch Day, September 15
- Medical devices/diagnostics Pitch Day, November 2
- Digital health technologies Pitch Day, December 14

For additional information and general questions, please email: InnovationFund@tdg.ucla.edu.

BIOMEDICAL COMPETITION 2017
- 106 LETTERS OF INTENT RECEIVED -
The UCLA Innovation Fund is partnering with Bow Capital and Osage University Partners to launch a campus-wide computer science competition.

Our mission is to assist the further development of early-stage software created at UCLA to the point of startup company formation. First and second place winners will receive investments to support commercialization activities that would not be supported by basic research grants.

First Place Winner: $75,000
Second Place Winner: $50,000

The award will be converted into equity upon company formation through a SAFE agreement. This is an opportunity to receive venture capital investment, which additionally provides business expertise and connections to further accelerate projects to market. In addition, winners will be offered Startup in a Box service provider support and a joint press release.

The competition will consist of an online application with finalists invited to pitch to a panel of judges in front of an audience.

2018 Process and Timeline (dates to be finalized):
- Online application opens, January 2
- Applications due, early March
- Finalists announced, late March
- Pitch Day, May

For additional information and general questions, please email: InnovationFund@tdg.ucla.edu.
UCLA ENTREPRENEURSHIP & NEW VENTURES

The Technology Development Group (TDG) supports UCLA’s research, education and service mission. Working with TDG is a complementary approach to traditional publishing that can facilitate the translation of UCLA discoveries into new products and services that have the potential to broadly benefit the public. Our office manages a large portfolio of technologies and active license agreements and has a rich history of startup company formation that we continue to build upon.

TDG Startups

<table>
<thead>
<tr>
<th>Year</th>
<th>Startups</th>
</tr>
</thead>
<tbody>
<tr>
<td>FY2013</td>
<td>15</td>
</tr>
<tr>
<td>FY2014</td>
<td>17</td>
</tr>
<tr>
<td>FY2015</td>
<td>22</td>
</tr>
<tr>
<td>FY2016</td>
<td>27</td>
</tr>
<tr>
<td>FY2017</td>
<td>20</td>
</tr>
</tbody>
</table>

ENTREPRENEURSHIP & NEW VENTURES TEAM

Thomas Lipkin, PhD  
Dir. of Entrepreneurship & New Ventures  
thomas.lipkin@tdg.ucla.edu

David Drasin, PhD  
New Ventures Principal  
david.drasin@tdg.ucla.edu

Dave Harrison, MD, MBA  
Sr. Associate, New Ventures  
david.harrison@tdg.ucla.edu
UCLA STARTUPS

Licensing UCLA technology to startup companies enables UCLA to be a strong economic engine for the Los Angeles region, California and beyond. Below is a small sample of such startups that have agreed to be showcased.

Aneeve Nanotechnologies, LLC

Aneeve Nanotechnologies is a startup company spun-out of UCLA and USC developing nano enabled electronics to bridge the gap between emerging and traditional platforms for communication and digital applications.

- Kos Galatsis PhD / MBA co-Founder
- Chongwu Zhou PhD co-Founder & Scientific Advisor
- Kang L. Wang PhD co-Founder & Scientific Advisor
- Chris Rutherglen PhD Principal Scientist

Aragon Pharmaceuticals, Inc.

(Acquired by J&J)

Aragon Pharmaceuticals is a privately held, small-molecule drug discovery company focused on developing breakthrough medicines for the treatment of hormonally-driven cancers.

- Michael Jung, PhD

Cellmic

Cellmic was formed in 2011 to commercialize advanced BioPhotonics technologies invented at the world-renowned research laboratory of Professor Aydogan Ozcan at UCLA.

- Aydogan Ozcan Founder & Director

Kite Pharma

Kite Pharma, founded in 2009, is a clinical-stage biopharmaceutical company focused on the development & commercialization of novel cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells.

- Andrian Bot, MD, PhD CSO
- Arie Belldegrun, MD, FACS Executive Chairman and Founder
- Owen Witte, MD Chairman of the Scientific Advisory Board
- James Economou, MD, PhD Member of the Scientific Advisory Board
- Antoni Ribas, MD, PhD Member of the Scientific Advisory Board

MAX BioPharma, Inc.

MAX BioPharma is a biotech start-up leveraging small molecule lipids to create the next generation of treatments for fatal and debilitating disorders.

- Farhad Parhami, PhD, MBA Scientific Founder
- Michael E. Jung, PhD Scientific Co-Founder
- William H. Matsui, MD Scientific Co-Founder
- Guido Eibl, MD Member of SAB
- Theodore J. Hahn, MD Member of SAB
- Jeffrey C. Wang, MD Member of SAB

Tribogenics

Tribogenics technology enables portable, compact X-ray solutions for applications in industrial testing, medical diagnosis, security screening and other industries.

- Carlos Camara, PhD Chief Scientist
- Warren Grundfest, MD Advisor
- Seth Putterman, PhD Advisor
ISSUED PATENTS IN THE UNITED STATES
(2016 & 2017)

2016 ISSUED PATENTS (JULY 2015 - JUNE 2016)

Q3  Q4  Q1  Q2
35  33  31  25

2017 ISSUED PATENTS (JULY 2016 - JUNE 2017)

Q3  Q4  Q1  Q2
30  40  32  35

PATENT PROSECUTION TEAM

Charan Arora, JD, PhD
Chief Intellectual Property Officer
charanjit.arora@tdg.ucla.edu

Mary Trachta
Sr. Patent Prosecution Analyst
mtrachta@tdg.ucla.edu

Tamara Alcaraz
Patent Prosecution Analyst
tamara.alcaraz@tdg.ucla.edu

Shemekia Brown
Patent Prosecution Analyst
shemekia.brown@tdg.ucla.edu

Deb Kowshik, JD
Patent Prosecution Analyst
debolina.kowshik@tdg.ucla.edu

Lily Yu
Patent Prosecution Analyst
lily.yu@tdg.ucla.edu
UCLA TEAM REPORTS POSITIVE TOPLINE RESULTS FROM DOUBLE-BLIND TRIAL OF NEUROSIGMA’S NON-INVASIVE eTNS SYSTEM FOR TREATMENT OF PEDIATRIC ADHD

NeuroSigma, Inc. (NeuroSigma) announced that on Friday, October 27, 2017, at the Annual Meeting of the American Academy of Child and Adolescent Psychiatry (AACAP), James McGough, M.D., M.S., presented the results of a double-blind randomized controlled trial of external Trigeminal Nerve Stimulation (eTNS®) for treating pediatric Attention Deficit Hyperactivity Disorder (ADHD). Dr. McGough, Professor of Clinical Psychiatry at the Semel Institute for Neuroscience and Human Behavior (Semel Institute) and David Geffen School of Medicine at the University of California, Los Angeles (UCLA), was the Co-Principal Investigator for the trial. Sandra Loo, Ph.D., Associate Professor at the Semel Institute and David Geffen School of Medicine at UCLA, was the Principal Investigator for the trial. Leon Ekchian, Ph.D., Head of the Neurology Department and President and CEO of NeuroSigma, was the Co-Principal Investigator.

The trial investigated the effects of eTNS on ADHD as the sole treatment, or “monotherapy.” A total of 62 children were enrolled in the trial and used the eTNS therapy each night, at home, for four weeks. The trial’s primary endpoint assessment, the ADHD-RS, showed that subjects randomized to active treatment had a statistically significant improvement in their ADHD symptoms compared with the sham group (p = 0.005). The CGI-I scale, a secondary endpoint, also demonstrated statistically significant improvements in ADHD symptoms among subjects randomized to the treatment group (p = 0.003). Side effects were generally mild and transient.

The U.S. National Institute of Mental Health (NIMH) provided independent grant funding to support this double-blind randomized controlled trial of eTNS for treating children with ADHD, ages 8 to 12. NeuroSigma provided the eTNS systems for the trial.

The scientific basis for this double-blind trial was established by an earlier open label trial conducted at UCLA, with funding and eTNS systems provided by NeuroSigma. In that trial, Dr. McGough and his team found significant improvements in the symptoms of ADHD and cognition in children treated with eTNS. A report of the trial in the journal Brain Stimulation summarized the results on 24 youths, ages 7 to 14, who had enrolled in an eight-week open trial of eTNS administered nightly during sleep. Significant improvements were seen on the ADHD-RS (p < 0.0001) and the parent-completed Conner’s Global Index (p < 0.0001) compared to baseline. Improvements were also noted on computerized tests of cognition.

“ADHD is estimated to affect 9.5% of school age children and 4.4% of adults, and our current treatments primarily include psychostimulant medications and behavioral therapies. While there is great demand for non-medication approaches to ADHD, most popular alternatives are not linked to any mechanistic understanding of brain processes and similarly lack significant scientific evidence to support their use. I am excited to have found a significant improvement in ADHD symptoms in our double-blind randomized clinical trial of this neuromodulation treatment,” said Dr. McGough. “In both our open label and double-blind trials, TNS was well accepted by patients and families, treatment compliance was high, and there were no clinically meaningful side effects or adverse events.”

“We congratulate Drs. McGough and Loo and their team for completing this important clinical trial. Using rigorous, state-of-the-art methods, they found a clear superiority in the use of active eTNS over sham treatment. Their findings advance the evidence that eTNS addresses both the cognitive and behavioral aspects of ADHD, which is an exciting development in the neuromodulation field,” said Ian Cook, M.D., Chief Medical Officer at NeuroSigma.

“The core value proposition of eTNS is effective non-pharmacological treatment with minimal side-effects. We are very pleased with the results of this double-blind trial and applaud the dedication and efforts of the UCLA team. Following FDA approval, we look forward to offering parents a non-pharmacological treatment option for pediatric ADHD in the United States,” said Leon EKchian, Ph.D., President and CEO of NeuroSigma.

###

NeuroSigma is a California-based life sciences company focused on commercialization of its non-invasive eTNS technology for the treatment of neuropsychiatric and neurological disorders. The Monarch eTNS System® has received CE mark approval in the European Union for ADHD for children age 7 and older and as adjunctive therapy for depression and epilepsy, as well as regulatory approvals in Canada and Australia.

CAUTION: In the United States, eTNS is an investigational device and is limited by Federal law to investigational use.


TTO: Emily Loughran
Lead Inventor: Christopher M DeGiorgio
School: UCLA School of Medicine, Department of Neurology
CENTER IN FUNCTION ACCELERATED NONOMATERIAL ENGINEERING (FAME) SECURES NEARLY $7.3 MILLION

Representing the largest single industry-sponsored extramural award of the 2017 fiscal year, TDG’s Industry Sponsored Research team, represented by Assistant Director Winston Lin, was proud to support Professor Jane Chang (William F. Seyer Chair in Materials Electrochemistry in the Department of Chemical Engineering) to secure nearly $7.3 million for the fifth and final year of support for the Center on Function Accelerated nanoMaterial Engineering (FAME). FAME is one of six university-based research centers established by the Semiconductor Research Corporation through its Semiconductor Technology Advanced Research network (STARnet). SRC and STARnet is a consortium of leading United States-based semiconductor and related technology corporations funded in cooperation with DARPA to maintain American leadership in semiconductor technology essential for commercial innovations, security and intelligence. FAME established an interdisciplinary network to revolutionize semiconductor technologies by developing new nonconventional atomic scale engineered materials and structures of multi-function oxides, metals and semiconductors to accelerate innovations in analog, logic and memory devices. To date FAME has secured nearly $35 million in research support from SRC to establish leading competencies of nonconventional materials through sponsored research across multiple departments within the UCLA School of Engineering and Applied Sciences and the Division of Physical Sciences partnering with dozens of additional faculty researchers populating 16 universities across the United States. Participating universities include: UC Berkeley, UC Irvine, US Riverside, and UC Santa Barbara, along with Caltech, Columbia, Cornell, MIT, Stanford, Purdue, Rice, North Carolina State, West Virginia and Yale.

Brian Roe, personal communication, November 30, 2017
ISR AWARDS
FY 13 - 17

ISR Award Total

Millions

<table>
<thead>
<tr>
<th>FY2013</th>
<th>FY2014</th>
<th>FY2015</th>
<th>FY2016</th>
<th>FY2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>$39.81</td>
<td>$39.13</td>
<td>$44.08</td>
<td>$40.54</td>
<td>$48.17</td>
</tr>
</tbody>
</table>

ISR Awards

<table>
<thead>
<tr>
<th>FY2013</th>
<th>FY2014</th>
<th>FY2015</th>
<th>FY2016</th>
<th>FY2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>233</td>
<td>241</td>
<td>248</td>
<td>241</td>
<td>256</td>
</tr>
</tbody>
</table>
LICENSING & TECHNOLOGY TRANSFER TEAM

Emily Loughran, MBA
Sr. Director Licensing & Strategic Alliances
eloughran@tdg.ucla.edu

Mark Wisniewski, MS, MBA
Sr. Director, Bio Pharmaceuticals
mark.wisniewski@tdg.ucla.edu

Angela Kujak, JD
Director of Contracts
angela.kujak@tdg.ucla.edu

Earl Weinstein, PhD
Associate Director, Licensing
eweinstein@tdg.ucla.edu

Tariq Arif, JD, MBA, MSc
Tech Transfer Officer, Life Sciences
tariq.arif@tdg.ucla.edu

Ed Beres
Tech Transfer Officer, Physical Sciences
edward.beres@tdg.ucla.edu

Scott Davis
Tech Transfer Officer, Physical Sciences
scott.davis@tdg.ucla.edu

Joel Kehle
Tech Transfer Officer, (Database & Comp Science)
joel.kehle@tdg.ucla.edu

Lukasz Kowalik, PhD
Tech Transfer Officer, Life Sciences
lukasz.kowalik@tdg.ucla.edu

LICENSES BY SCHOOL
FY 2017

ISR AWARDS BY SCHOOL
FY 2017
BOEHRINGER-INGELHEIM & UCLA COLLABORATE ON CANCER VACCINE PLATFORM FOR IMMUNOTHERAPY

Boehringer-Ingelheim (BI) and UCLA are collaborating on a several-year effort to develop a new cancer vaccine platform for immunotherapy. The key idea involves delivery of the vaccine in the form of self-replicating RNA that is protected by a protein shell. Up to the present, most vaccines have been formulated directly as protein antigen, or as messenger (m)RNA coding for the antigen, with the protein or RNA complexed by liposomes or charged polymers. In the BI-UCLA platform, however, a self-replicating RNA coding for the antigen is packaged in vitro – from purified components in a test tube – into stable, monodisperse, virus-like particles (VLPs) by simply mixing it under the right buffer conditions with the capsid protein of a particular plant virus that has been shown by the UCLA lab to package non-viral RNA of any sequence as long as its length is between 2500 and 4500 nucleotides. The mRNA for the cancer vaccine has been made self-replicating by inserting it into the non-infectious genome of an insect RNA virus that codes for the enzyme that replicates it – along with the mRNA for the cancer vaccine – up to one-million-fold, once it is in a host cell. Cell culture results confirm that antigen-presenting cells of the immune system – specifically, dendritic cells – are strongly activated when they take up these VLPs, and preliminary mouse studies indicate a significant T-cell response (relative to that elicited by the mRNA vaccine, or by the self-replicating RNA vaccine without the benefit of protein shell protection). Another advantage of in vitro reconstituted virus-like particles is that they can be modified for enhanced uptake by dendritic cells, and can be made to co-package adjuvants boosting the immune response to the antigen.

This work involves collaboration between the research group of UCLA PI Professor William M. Gelbart, and BI teams at their research labs in Ridgefield, Connecticut, as well as in Biberach, Germany, and Vienna, Austria.

Bill Gelbart, personal communication, October 27, 2017

TTO: Earl Weinstein
Lead Inventors: William Gelbart & Charles Knobler
School: UCLA Department of Chemistry & Biochemistry
FOXCONN, KEYSSA®, AND SAMSUNG INTRODUCE DISRUPTIVE “CONNECTED WORLD” SMARTPHONE ECOSYSTEM

Connected World Will Define How Next-Gen Mobile Devices Share Gigabits of Data, Without Wi-Fi or Wires

Initiative to Radically Simplify Engineering and Design Requirements Around Consumer IoT Devices and Applications, Including for Mobile, Home and Automotive Use Cases

Campbell, Calif. – August 16, 2017 – Today, a group of leading technology companies and Keyssa investors announced a “Connected World” initiative focused on extremely high-speed data transfer between mobile devices and the increasing number of connected devices. The companies and investors involved include Hon Hai Precision Industry Co., Ltd, the world’s largest electronics manufacturing company, also known as Foxconn; Keyssa®, the leader in high-speed, contactless connectivity; Samsung, a leader in connected products and solutions for automakers and consumers; and Tony Fadell, inventor of the iPod, iPhone, and founder of Nest.

About the Specification
Core to developing the Connected World ecosystem is Keyssa’s proprietary Kiss Connectivity. Kiss Connectors are proprietary, tiny, low-cost, low-power, solid-state, embeddable electromagnetic connectors that securely move huge files at high bandwidth between devices.

A new technical specification will detail all the requirements necessary to standardize next generation mobile connectivity across devices. The goal is to improve functionality, engineering and design by moving beyond decades-old limitations imposed by wires and Wi-Fi. Connected World will simplify and drastically speed up the way smartphones, peripherals, accessories, the smart home and cars share and sync large data sets – allowing gigabit-size data transfers to take place simply by briefly touching the devices together.

The specification will encompass critical items including device mechanical attach mechanisms, high-bandwidth electromagnetic channel requirements, and device compliance testing. Keyssa will offer a license to all of its IP that reads on the specification, including its system-level patents. A reference design will be available for manufacturers when the specification is made public.

Comments From Key Participants
“Foxconn sees substantial consumer value when our devices can seamlessly connect,” said Dr. Chen, CTO. “We envision a world where devices are connected by simply touching each other, and in that simple touch, gigabits of information are transferred and shared. Keyssa’s technology can enable this vision.”

“It’s been 10 years since the first iPhone appeared, a device that defines the center of our digital life,” says iPhone inventor Tony Fadell. “But in terms of connectivity and device-to-device interaction, we’re still barely scratching the surface of what’s possible. Soon we will be able to see very high-speed connectivity between the automobile, the home and the phone truly creating a connected world without requiring expensive mobile data connections.”

“We are happy to be working with our investors, all of whom have been unbelievably supportive throughout the development of this innovative technology,” says Eric Almgren, CEO Keyssa. “We can all envision a world where devices are free from wires and mechanical connectors without sacrificing bandwidth or security. This has been our vision from day one.”

Acting as advisor to the “Connected World” initiative is Tony Fadell, inventor of the iPod, iPhone, and founder of Nest, the company that pioneered the “Internet of things.” Tony is an early investor in Keyssa, served as Chairman of the Board and currently serves as Advisor to the Company.

For more information on the Connected World initiative, please contact Keyssa at info@keyssa.com.

To learn more about Hon Hai Precision Industry Co., Ltd., trading as Foxconn Technology Group, Samsung Electronics Co., Ltd., Keyssa and Tony Fadell, please visit the full press release cited below.


TTO: Emily Loughran
Lead Inventor: Mau-Chung Frank Chang
School: UCLA Department of Electrical Engineering
UCLA TDG EVENT ATTENDANCE
FY 15 - 17

OPERATIONS & MARKETING TEAMS

Tim Grauerholz, MBA
CFO & COO
tim.grauerholz@tdg.ucla.edu

Laura Van Nostrand
Dir. Human Resources
lauravn@tdg.ucla.edu

Elizabeth Bazarko
Marketing Manager
elizabeth.bazarko@tdg.ucla.edu

Kristen Robertson
Sr. Financial Analyst
kristen.robertson@tdg.ucla.edu

Jasmine Endeman
Operations & HR Analyst
jasmine.endeman@tdg.ucla.edu

Heather Felix, MS, MBA
Campus Relations Manager
heather.felix@tdg.ucla.edu

Nancy Levitan
Executive Assistant to Amir Naiberg
nancy.levitan@tdg.ucla.edu

Jude Anchang
Operations Support Analyst
jude.anchang@tdg.ucla.edu

Liz Peek, PhD
Technology Transfer Associate
liz.peek@tdg.ucla.edu

Matt Vicari
IT Support
desktopsupport@tdg.ucla.edu

UPCOMING EVENTS IN 2018

UCLA TDG First Friday’s
Dates: The First Friday of the month (except January & July)
Location: Hammer Building, Suite 820-20

6th Annual UCLA MedTech Partnering Conference
Date: March 6, 2018
Location: CNSI

Pathways to Commercialization
Date: TBD / May, 2018
Location: CNSI

UCLA TDG Innovation Day
Date: TBD
Location: Luskin Center
The UCLA Technology Development Group serves as a campus-wide gateway to Innovation, Research and Entrepreneurship. Our mission is to:

• Promote UCLA innovation, research, education and entrepreneurship to benefit society
• Create economic value to support UCLA’s scholarly and educational missions and the State of California
• Lead UCLA’s research community to bring innovation to market

Contact us at:

310.794.0558
innovation@tdg.ucla.edu
www.tdg.ucla.edu